Clinical trials: Risperidone, completed
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
The purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of Paliperidone…
- Trial name
- PsiProsper (NCT03666715)
- Testing
- Oral Antipsychotics (OAPs), Paliperidone Palmitate 1-Month Formulation (PP1M)
- Where
- Portugal
- Volunteers
- 55 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Schizophrenia
Different Safety Profile of Risperidone and Paliperidone Extended-release
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a…
- Trial name
- NCT01284959
- Testing
- risperidone, paliperidone ER
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
The proposed study has been planned to evaluate the effect of add-on ramelteon on sleep pattern/quality and circadian rhythm disruption in patients with schizophrenia.
- Trial name
- NCT03075657
- Testing
- Risperidone, Risperidone and Ramelteon, Haloperidol
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple…
- Trial name
- NCT05779241
- Testing
- LYN-005, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- Lyndra Inc.
Healthy
Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
A Single-dose, Randomized, two-Period, Cross over Study
- Trial name
- NCT01064232
- Testing
- Risperidone
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Attention, Visual Perceptual Weakness
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS
- Conditions
- Attention, Visual Perceptual Weakness, Social Behavior, Fluency Disorder
- Trial name
- tDCS&ASD (NCT06368726)
- Testing
- tDCS or Transcranial Direct Current Stimulation, Risperidone
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Despite recent advances in the understanding and treatment of schizophrenia, this devastating disease still affects one percent of world's population.
- Trial name
- CBD-IS (NCT02051387)
- Testing
- Cannabidiol CR, Cannabidiol, Amisulpride
- Where
- 2 sites in Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia
Add-On Therapy to Risperidonein Schizophrenia
These results suggest that the DA neuroprotection provided by DM in the inflammation-related neurodegenerative models is not mediated through the NMDA receptor.
- Trial name
- DM (NCT01189006)
- Testing
- Dextromethorphan
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Cheng-Kung University Hospital
Schizophrenia, Diabetes
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
- Trial name
- NCT00287820
- Testing
- Olanzapine, risperidone
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
One Year Drug Treatment in First-Episode Schizophrenia
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
- Trial name
- NCT00159081
- Testing
- Haloperidol, Risperidone (drug)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorders, Schizophrenia
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the…
- Trial name
- NCT00821600
- Testing
- risperidone IR and LAI formulation
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Unipolar Depression
Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression
The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.
- Trial name
- NCT00179244
- Testing
- Rispridone (drug) and Bupropion ER (drug)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Schizophrenia, Psychotic Disorders
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.
- Trial name
- NCT00034775
- Testing
- risperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.